Solar stocks surge after Treasury tightens clean energy tax credit rules
Director Bridget A. Ross of LeMaitre Vascular Inc (NASDAQ:LMAT), a $2.14 billion medical device company, sold 2,500 shares of common stock on August 8, 2025, at a price of $94. The total value of the sale was $235,000. According to InvestingPro analysis, the stock is currently trading above its Fair Value, with multiple valuation metrics suggesting premium pricing.
On the same day, Ross also exercised options to acquire 2,500 shares of LeMaitre Vascular at an exercise price of $37.29, for a total value of $93,225. The company has demonstrated strong performance with 14% revenue growth and maintains a "GREAT" financial health score.
Following these transactions, Ross directly owns 2,916 shares of LeMaitre Vascular. InvestingPro subscribers can access 15+ additional insights and detailed valuation metrics for LMAT, including comprehensive Fair Value analysis and growth projections.
In other recent news, LeMaitre Vascular reported strong financial results for the second quarter of 2025, surpassing analysts’ expectations. The company achieved an earnings per share (EPS) of $0.60, exceeding the forecasted $0.57, which marks a 5.26% earnings surprise. Revenue for the quarter reached $64.2 million, surpassing both Cantor Fitzgerald’s estimate of $62.3 million and the FactSet consensus of $62.5 million. This revenue reflects approximately 15% year-over-year growth, all of which was organic. Cantor Fitzgerald maintained its Neutral rating on LeMaitre Vascular, with a price target set at $95.00. These developments highlight the company’s strong performance in the recent quarter.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.